Chemical chaperones: mechanisms of action and potential use.

An increasing number of studies indicate that low-molecular-weight compounds can help correct conformational diseases by inhibiting the aggregation or enable the mutant proteins to escape the quality control systems, and thus their function can be rescued. The small molecules were named chemical chaperones and it is thought that they nonselectively stabilize the mutant proteins and facilitate their folding. Chemical chaperones are usually osmotically active, such as DMSO, glycerol, or deuterated water, but other compounds, such as 4-phenylbutiric acid, are also members of the chemical chaperone group. More recently, compounds such as receptor ligands or enzyme inhibitors, which selectively recognize the mutant proteins, were also found to rescue conformational mutants and were termed pharmacological chaperones. An increasing amount of evidence suggests that the action of pharmacological chaperones could be generalized to a large number of misfolded proteins, representing new therapeutic possibilities for the treatment of conformational diseases. A new and exciting strategy has recently been developed, leading to the new chemical group called folding agonist. These small molecules are designed to bind proteins and thus restore their native conformation.

[1]  L N Csonka,et al.  Physiological and genetic responses of bacteria to osmotic stress. , 1989, Microbiological reviews.

[2]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[3]  W. Crowley,et al.  Male hypogonadotropic hypogonadism. , 1993, Endocrinology and metabolism clinics of North America.

[4]  D. Clarke,et al.  Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. , 1994, The Journal of biological chemistry.

[5]  Satoshi Ishii,et al.  Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease , 1995 .

[6]  S. Brusilow,et al.  Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. , 1995, Blood.

[7]  D. Clarke,et al.  P-glycoprotein , 1995, The Journal of Biological Chemistry.

[8]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[9]  William J. Welch,et al.  Influence of molecular and chemical chaperones on protein folding. , 1996, Cell stress & chaperones.

[10]  A S Verkman,et al.  Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. , 1996, Cell stress & chaperones.

[11]  J. Wine,et al.  Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.

[12]  W. Welch,et al.  Correcting temperature-sensitive protein folding defects. , 1997, The Journal of clinical investigation.

[13]  D. Bichet,et al.  Nephrogenic diabetes insipidus. , 2001, Annual review of physiology.

[14]  S. Gellman,et al.  Artificial Chaperone-assisted Refolding of Citrate Synthase* , 1998, The Journal of Biological Chemistry.

[15]  E. Bertram,et al.  Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo. , 1998, Journal of immunology.

[16]  A. Verkman,et al.  Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. , 1998, The Journal of clinical investigation.

[17]  L. Whitesell,et al.  Molecular chaperones: biology and prospects for pharmacological intervention. , 1998, Pharmacological reviews.

[18]  K. Kirk,et al.  Activation of DeltaF508 CFTR in an epithelial monolayer. , 1998, The American journal of physiology.

[19]  S. Kaler Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. , 1998, The American journal of clinical nutrition.

[20]  A S Verkman,et al.  Misfolding of Mutant Aquaporin-2 Water Channels in Nephrogenic Diabetes Insipidus* , 1999, The Journal of Biological Chemistry.

[21]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[22]  I. Baskakov,et al.  Trimethylamine N-Oxide-induced Cooperative Folding of an Intrinsically Unfolded Transcription-activating Fragment of Human Glucocorticoid Receptor* , 1999, The Journal of Biological Chemistry.

[23]  D. Clarke,et al.  Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. , 1999, Biochimica et biophysica acta.

[24]  P. Fraser,et al.  Manipulating the Amyloid-β Aggregation Pathway with Chemical Chaperones* , 1999, The Journal of Biological Chemistry.

[25]  C. January,et al.  Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome , 1999, The Journal of Biological Chemistry.

[26]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.

[27]  R. Kopito,et al.  Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.

[28]  T. Wisniewski,et al.  Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.

[29]  D. Perlmutter,et al.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Bichet,et al.  Pharmacological chaperones: a new twist on receptor folding. , 2000, Trends in pharmacological sciences.

[31]  S. Angers,et al.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.

[32]  C. Partridge,et al.  Identification and Pharmacological Correction of a Membrane Trafficking Defect Associated with a Mutation in the Sulfonylurea Receptor Causing Familial Hyperinsulinism* , 2001, The Journal of Biological Chemistry.

[33]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Galietta,et al.  Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. , 2001, Journal of cell science.

[35]  D. Chuang,et al.  Natural Osmolyte Trimethylamine N-Oxide Corrects Assembly Defects of Mutant Branched-chain α-Ketoacid Decarboxylase in Maple Syrup Urine Disease* , 2001, The Journal of Biological Chemistry.

[36]  A S Verkman,et al.  Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds* 210 , 2001, The Journal of Biological Chemistry.

[37]  P. Goloubinoff,et al.  Chemical Chaperones Regulate Molecular Chaperones in Vitro and in Cells under Combined Salt and Heat Stresses* , 2001, The Journal of Biological Chemistry.

[38]  G. Wiens,et al.  Recovering Antibody Secretion Using a Hapten Ligand as a Chemical Chaperone* , 2001, The Journal of Biological Chemistry.

[39]  M. K. Chattopadhyay,et al.  Chaperone-like properties of lysophospholipids. , 2001, Biochemical and biophysical research communications.

[40]  Robert J. Desnick,et al.  Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.

[41]  M. Boyle,et al.  Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  R. Rudolph,et al.  The non‐ionic detergent Brij 58P mimics chaperone effects , 2002, FEBS letters.

[43]  Protein origami: therapeutic rescue of misfolded gene products. , 2002, Molecular interventions.

[44]  Jussi Taipale,et al.  Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. , 2002, Genes & development.

[45]  P. Conn,et al.  Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. , 2002, The Journal of clinical endocrinology and metabolism.

[46]  Byung-Eun Kim,et al.  A Conditional Mutation Affecting Localization of the Menkes Disease Copper ATPase , 2002, The Journal of Biological Chemistry.

[47]  M. Bouvier,et al.  Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation , 2002, The EMBO journal.

[48]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  I. Kanazawa,et al.  Chemical Chaperones Reduce Aggregate Formation and Cell Death Caused by the Truncated Machado–Joseph Disease Gene Product with an Expanded Polyglutamine Stretch , 2002, Neurobiology of Disease.

[50]  C. Hollak,et al.  Gaucher disease: from fundamental research to effective therapeutic interventions. , 2003, The Netherlands journal of medicine.

[51]  W. El-Deiry,et al.  Restoring p53-Dependent Tumor Suppression , 2003, Cancer biology & therapy.

[52]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[53]  Xinbin Chen,et al.  Isolation and Characterization of Fourteen Novel Putative and Nine Known Target Genes of the p53 Family , 2003, Cancer biology & therapy.

[54]  D. Selkoe Folding proteins in fatal ways , 2003, Nature.

[55]  I. Braakman,et al.  Quality control in the endoplasmic reticulum protein factory , 2003, Nature.

[56]  Claudio Soto,et al.  Unfolding the role of protein misfolding in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[57]  O. Chilson,et al.  Perturbation of folding and reassociation of lactate dehydrogenase by proline and trimethylamine oxide. , 2003, European journal of biochemistry.

[58]  Christopher M. Tan,et al.  Appropriate Polarization following Pharmacological Rescue of V2 Vasopressin Receptors Encoded by X-linked Nephrogenic Diabetes Insipidus Alleles Involves a Conformation of the Receptor That Also Attains Mature Glycosylation* , 2003, Journal of Biological Chemistry.

[59]  H. Takagi,et al.  Gene Dosage Effect of l-Proline Biosynthetic Enzymes on l-Proline Accumulation and Freeze Tolerance in Saccharomyces cerevisiae , 2003, Applied and Environmental Microbiology.

[60]  A. Fersht,et al.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Seiichiro Ogawa,et al.  Chemical chaperone therapy for brain pathology in GM1-gangliosidosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Stockley,et al.  α1-Antitrypsin deficiency • 3: Clinical manifestations and natural history , 2004, Thorax.

[63]  Neena Singh,et al.  Doxycycline and protein folding agents rescue the abnormal phenotype of familial CJD H187R in a cell model. , 2004, Brain research. Molecular brain research.

[64]  Michel Bouvier,et al.  Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.

[65]  L. Cebotaru,et al.  Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. , 2004, Physiological genomics.

[66]  A. Fersht,et al.  Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". , 2004, Journal of molecular biology.

[67]  Y. Nomura,et al.  Sodium 4-Phenylbutyrate Protects against Cerebral Ischemic Injury , 2004, Molecular Pharmacology.

[68]  S. Shyng,et al.  Sulfonylureas Correct Trafficking Defects of ATP-sensitive Potassium Channels Caused by Mutations in the Sulfonylurea Receptor* , 2004, Journal of Biological Chemistry.

[69]  I. Goldenberg,et al.  Long QT syndrome. , 2008, Journal of the American College of Cardiology.